The PRIPS study: screening battery for subjects at risk for Parkinson's disease. - Wikidata - wikimedia - TriplyDB

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

http://www.wikidata.org/entity/Q34361343

about

Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned Neuroimaging in pre-motor Parkinson's disease Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study Individual and joint prevalence of three nonmotor symptoms of PD in the US general population Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?Meta-analyses on prevalence of selected Parkinson's nonmotor symptoms before and after diagnosis Identifying the clusters within nonmotor manifestations in early Parkinson's disease by using unsupervised cluster analysis.Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection.Computer keyboard interaction as an indicator of early Parkinson's disease Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.Is there a need to redefine Parkinson's disease?Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson's Disease The relevance of pre-motor symptoms in Parkinson's disease.The Concept of Prodromal Parkinson's Disease.Laboratory assessments in the course of Parkinson's disease: a clinician's perspective.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Advances in Biomarker Research in Parkinson's Disease.Biomarkers in Prodromal Parkinson Disease: a Qualitative Review.Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community.Benefit on motor and non-motor behavior in a specialized unit for Parkinson's disease.Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective.Use of monoamine oxidase inhibitors in chronic neurodegeneration.Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.Olfaction and incident Parkinson disease in US white and black older adults.Frequency and profile of Parkinson's disease prodromi in patients with malignant melanoma.Olfactory Dysfunction Evaluation Is Not Affected by Comorbid Depression in Parkinson's Disease.Before the tremor: premotor symptoms of Parkinson's disease.Risk factors and prodromal markers and the development of Parkinson's disease.Among Early Appearing Non-Motor Signs of Parkinson's Disease, Alteration of Olfaction but Not Electroencephalographic Spectrum Correlates with Motor Function.Echogenicity of basal ganglia structures in different Huntington's disease phenotypes.The Changing Landscape of Parkinson Epidemiologic Research.The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study).Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?A population-based study on combined markers for early Parkinson's disease.Safinamide: an add-on treatment for managing Parkinson's disease.

P2860

Q26738357-6FA36B36-ECD2-425A-A114-DF2C3914B21B Q33676222-E2FE07E8-4FDB-42BC-8F65-E4107D624CAC Q34043770-387186EC-03EC-46A4-8ADE-09B2F1BCC40B Q34281376-12BE27D9-6E91-43AC-99E2-E049CD6FDB34 Q34553777-5DEC7CFC-B2DB-47CB-AADD-B5154FD819A5 Q34562789-0F1E503A-8A61-4D02-8C36-F2FB65E54454 Q35066107-FB2B157B-299A-4738-8559-66612E6A2795 Q35124218-7B7C940C-B5AD-41FF-A6A4-4E970F95E711 Q35671020-BFFFAD89-0DB6-4EB5-A667-78CFBD3EB361 Q37054007-8D851A3D-2B43-4783-A425-F12DE84B3523 Q37310810-CE199CA0-6FC6-4049-A1AE-3FC2FC7F495F Q37374203-FCA0A400-67DC-4D25-B378-EF60B1A60F64 Q38110209-747A2708-92C5-467E-BE84-A4A43D62DC68 Q38384109-32F369C7-CFAB-403C-A5E4-51109F92EBB0 Q38594857-8BEDDBD4-2B9B-435E-9B5C-0D8A0D6D9F5D Q38612230-C6D25351-1DEA-4294-93BB-686A4622ACAD Q38634768-F3921F76-CF1E-46B4-B7DD-D2ECFC1AC8C8 Q38636630-D06965A0-3FFF-45F0-9CBD-6F993509457E Q38681599-5EAB97B3-B57B-41F0-A804-91EF81ECFC10 Q38788917-2AE40B04-0F64-4E6C-9AAD-42C528677E1B Q38858537-70BB0894-A765-4A3B-A83A-05345B6E5CFB Q38936527-EE8EBC75-FAA8-4240-BBE4-BDFA8ADD8E33 Q38947507-300201F8-0EB2-47D0-AD29-E969AD089C3F Q39044780-6755C7F6-9D40-42C5-B1A8-76AA4A298FD6 Q39304905-7CC15301-D7F8-429B-8C93-22CC4BAED241 Q39325939-D9B2FA30-E599-4A52-9F90-C9B27B168447 Q40055081-1C390D7D-ECD6-4E9C-B363-722F562EB278 Q41147841-1013F91F-D17E-432A-8CEF-547389583F7D Q41652414-C7D43BC8-1046-4767-BE5A-320E6CDF37B3 Q42837041-F5C98051-3D66-47FE-AC9A-1C4BE09271EC Q44252207-8EF11AEC-CDB9-4BD1-9A88-5D477A51F42C Q44447407-5BA0C447-1012-461B-AB55-8F7C01A8A991 Q45303272-40B40D2E-58B5-46C7-BE0B-55D41B31C6E8 Q47662113-E2C1B0DD-2D03-4747-A28C-059A32BBD835 Q48012488-4B8BABA2-6FE1-4006-8132-4B79FCFD8D5E Q48129130-B6FE02E0-3E0C-469B-9B17-D78F25237550 Q48397754-A392CAA4-A1AA-4BF3-9990-33A0296AFB24 Q52804779-8700E677-6B89-49D1-9A3C-C1CCDF7E2739

P2860

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

http://www.wikidata.org/entity/Q34361343

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

@ast

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

@en

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

@nl

type

label

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

@ast

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

@en

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

@nl

prefLabel

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

@ast

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

@en

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

@nl

P1433

Q34361343-CD32EE07-4F9B-490E-B258-8A7368C2F1BB

P1476

Q34361343-9ABE03A1-88FD-431F-AAEC-279DD954CFD7

P2093

Q34361343-3B6244A0-857B-47CD-A88E-B1F3038CF9F3

Q34361343-3DBB35FA-C86A-4E79-B69F-58AE8A0C2279

Q34361343-405FA2A7-679C-415C-9085-FEFE7C07E3F3

Q34361343-470A4367-8D22-4A76-A1D0-6A4845F475D3

Q34361343-5F0E166A-93C0-4509-8C89-87C53496B66A

Q34361343-63C206CD-9405-47D2-9866-07AC21F38877

Q34361343-9253FC12-6C68-4468-8F7C-597BE8B8B4B7

Q34361343-95497083-7941-46B2-B42D-253D785E4169

Q34361343-A243ABA7-D6CC-4C4D-8C51-A81E3F75085A

Q34361343-CAB93FD2-FD6E-486F-B6D3-FB4A0D22B974

P2860

Q34361343-04DCF65B-351F-4C0A-BF6E-A2B665A0C219

Q34361343-08F8F398-93F0-4A92-BDD4-F6E88E218726

Q34361343-146FA262-C4F6-4B53-ADE9-C41A71344E34

Q34361343-1605218D-426F-4C0A-A1DC-7FACAD558C39

Q34361343-1DB6EEFB-6838-4383-B693-D406FFBC15F7

Q34361343-1DFD3232-5769-477B-A35A-D812094F344B

Q34361343-2FC366D3-E427-488F-9102-442927A3EE72

Q34361343-6ED6B3A8-DB37-4B3D-8ED9-15592867F7D3

Q34361343-71EB6B41-0635-4BDF-ADFC-B318AD791888

Q34361343-7A320CAE-09B5-4AC2-A5F6-F80C52462D70

P304

Q34361343-6643AA7C-3014-459A-AF7D-9F2C855D7353

P31

Q34361343-FD2DD574-B321-4C3F-9E8A-2402FBEFE3B5

P356

Q34361343-BFD5E04B-C985-4C3D-868C-10D01ECAADD9

P433

Q34361343-C6D3241F-7B34-4F96-AD99-D01AA7E59B96

P478

Q34361343-D111C734-8CF3-4F32-86FE-2D4FF2B3B8ED

P50

Q34361343-28AF1403-DD61-4373-8F29-FC17E6C282AE

Q34361343-5120C8CA-6152-4D5A-9102-98A84B2760CD

Q34361343-6C6BC8F9-3D14-4E1F-ACDA-97EBF53D68E7

Q34361343-BD0DBDEF-8C18-47DF-9ED1-4F6E6710EBCC

P577

Q34361343-FEFDB50E-A739-497E-9565-88520C708730

P5875

Q34361343-A6DF3D9F-D755-4F74-9181-34F21AD7FE24

P698

Q34361343-8015ECD1-4199-4298-9119-923841D96943

P921

Q34361343-389D7F30-B68A-4976-A5F9-5945FB5B46E9

P356

J.1468-1331.2012.03798.X

P1433

European Journal of Neurology

P1476

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

@en

P2093

A Gaenslen

http://www.w3.org/2001/XMLSchema#string

D Berg

http://www.w3.org/2001/XMLSchema#string

H Huber

http://www.w3.org/2001/XMLSchema#string

H Stockner

http://www.w3.org/2001/XMLSchema#string

I Liepelt-Scarfone

http://www.w3.org/2001/XMLSchema#string

J Godau

http://www.w3.org/2001/XMLSchema#string

K Seppi

http://www.w3.org/2001/XMLSchema#string

K Srulijes

http://www.w3.org/2001/XMLSchema#string

PRIPS study group

http://www.w3.org/2001/XMLSchema#string

S Behnke

http://www.w3.org/2001/XMLSchema#string

P2860

Screening of olfactory function with a four-minute odor identification test: reliability, normative data, and investigations in patients with olfactory loss.

What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study.

Biomarkers for the early detection of Parkinson's and Alzheimer's disease.

Transcranial sonography in movement disorders.

Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly.

Olfactory impairment in presymptomatic Alzheimer's disease.

Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons.

Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging.

Prevalence of olfactory dysfunction: the skövde population-based study.

Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study.

P304

102-108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1468-1331.2012.03798.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Klaus Fassbender

Philipp Mahlknecht

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230594029

http://www.w3.org/2001/XMLSchema#string

P698

22852790

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease